(b) unless contemplated under this Bond Agreement and unless it constitutes a permitted substitution of said Project Document, agree to or permit the early termination of, or agree to a change, amendment, modification or waiver of, any Project Document and/or any right or interest therein, which is likely to have a Material Adverse Effect (in the opinion of the Bond Trustee), or assign any of its rights or delegate any of its obligations under any Project Document;
(d) incur or permit to remain outstanding, any new Financial Indebtedness (whether secured or unsecured) other than (i) any Financial Indebtedness arising under the Bond Issue, (ii) any Financial Indebtedness arising under the Permitted Bank Debt (as contemplated under this Bond Agreement), or (iii) indebtedness arising in the ordinary course of business for working capital puiposes and as part of the daily operation of the Issuer;
(e) grant any loans, guarantees or other financial assistance or support to any third party, except for (i) as contemplated under this Bond Issue; (ii) as contemplated under the Permitted Bank Debt; and (iii) guarantees issued in the ordinary course of business; and
(f) enter into any contracts or arrangements to hedge oil prices for speculative purposes, unless at market prices and not having a Material Adverse Effect.
13.6 Hydrocarbon Resources Covenants
(a) Maintenance and Insurance The Issuer shall provide for reasonable and satisfactory maintenance and insurance of the Hydrocarbon Resources and all relevant assets related thereto at all times. The Hydrocarbon Resources and all relevant assets related thereto shall be adequately insured in a manner consistent with customary and prudent industry standards for companies operating similar businesses of similar size.
(b) Disposed o f Hydrocarbon Resources
The Issuer shall not and shall ensure that no other Group Company shall sell or otherwise dispose of, directly or indirectly, any part of the Hydrocarbon Resources with commercial production if such sale would have a Material Adverse Effect.
21
